Vertex Pharmaceuticals Incorporated VRTX
526.19
3.81
0.73%
as of 25 Sep
- Market cap
- $132.3B
- P/E
- 30.4×
Follow VRTX
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
Vertex Pharmaceuticals Incorporated (VRTX) P/S ratio
As of 25 September 2026, Vertex Pharmaceuticals Incorporated (VRTX) trades at a P/S ratio of 10.6×. Over the past ten years it has ranged from 6.4× (October 2021) to 54.4× (March 2015); the current reading is higher than 40% of that period. That is below the Biotechnology industry median of 11.5× and above the Healthcare sector median of 3.8×.
P/S ratio, daily
Annual
| Period | P/S ratio | Change |
|---|---|---|
| FY2025 | 9.7× | 2.49% |
| FY2024 | 9.4× | (12.16%) |
| FY2023 | 10.7× | 30.82% |
| FY2022 | 8.2× | 9.78% |
| FY2021 | 7.5× | (24.49%) |
| FY2020 | 9.9× | (26.72%) |
| FY2019 | 13.5× | (2.35%) |
| FY2018 | 13.8× | (9.57%) |
| FY2017 | 15.3× | 42.04% |
| FY2016 | 10.8× | (63.40%) |
Quarterly
| Period | P/S ratio | Change |
|---|---|---|
| Jun 2026 | 10.0× | 7.81% |
| Mar 2026 | 9.3× | (3.86%) |
| Dec 2025 | 9.7× | 13.12% |
| Sep 2025 | 8.5× | (14.68%) |
| 42 more quarters | Free account |
Against its own ten years
Low 6.4×
High 54.4×
Ten-year median
11.9×
Current reading's percentile
40
P/S ratio against peers
| Company | P/S ratio |
|---|---|
| REGN Regeneron Pharmaceuticals, Inc. compare | 5.2× |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | 6.6× |
| ALNY Alnylam Pharmaceuticals, Inc. compare | 7.1× |
| RPRX Royalty Pharma PLC compare | 10.2× |
| VRTX Vertex Pharmaceuticals Incorporated | 10.6× |
| ARGX argenex SE compare | 11.2× |
| INSM Insmed, Inc. compare | 22.5× |
| MRNA Moderna, Inc. compare | 35.5× |
| RVMD Revolution Medicines, Inc. compare | 1,606× |
| Biotechnology industry median | 11.5× |
| Healthcare sector median | 3.8× |
| Market median | 2.0× |
What P/S ratio is
Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.
(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)
More on VRTX
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement